Travere Therapeutics, Inc. (TVTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$50.08-4.48%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Travere Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-2.3%

+10% or more+5%0%−5%−10% or less

3.16 → 3.09 EPS · FY ending Dec 31, 2027 · 8 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 8; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	234.41M
EPS	—	0.513
Annual ending 2026-12-31
Revenue	—	729.52M
EPS	—	-0.089
Annual ending 2027-12-31
Revenue	—	1.09B
EPS	—	3.088

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Progress on Everest Medicines partnership	A supporting condition in Travere Therapeutics, Inc.'s published investment case. The stated target is Successful development and commercialization progress by end 2026.	Intact	Everest partnership fails or stalls in 2026	Qualitative: Exclusive licensing agreement signed June 2026 Travere signed an exclusive licensing agreement with Everest Medicines for civorebrutinib in June 2026, advancing the partnership. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. The company formalized a strategic partnership with Everest Medicines through a licensing and collaboration agreement for civorebrutinib. This partnership supports pipeline expansion and global market access. The trajectory shows initial execution with partnership formation. Delivery assessment Oct 24, 2026
FILSPARI revenue growth and patient reach	A primary condition in Travere Therapeutics, Inc.'s published investment case. The stated target is >= $490 million total revenue in FY26.	Intact	Total revenue falls below $490 million in FY26	Revenue: $169.584M FY2026-Q2; GAAP. Published target: >= $490 million total revenue in FY26. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026169,584,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 674cb35f-f817-40b8-b7bf-1679c5ad1797. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. U.S. net product sales of FILSPARI grew from approximately $71.9 million in 2025-Q2 to $141.1 million in 2026-Q2, a 96% year-over-year increase. The company reported 2,012 new patient start forms in 2026-Q2, reflecting strong commercial momentum. Management's statements and financial results show delivering progress on expanding FILSPARI's market reach. Delivery assessment Oct 24, 2026
Achieve 2026 revenue guidance range	A primary condition in Travere Therapeutics, Inc.'s published investment case. The stated target is Revenue between $490 million and $550 million in FY26.	Intact	Revenue falls below $490 million in FY26	Revenue: $169.584M FY2026-Q2; GAAP. Published target: Revenue between $490 million and $550 million in FY26. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026169,584,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 674cb35f-f817-40b8-b7bf-1679c5ad1797. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$3.09

$4.85 → $3.09 · observed estimates

FY2027 revenue$1.09B

$0.97B → $1.09B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$4.85	$968,877,310	8 / 14
2026-07-25	$4.77	$963,850,130	8 / 14
2026-07-26	$2.38	$963,851,341	8 / 11
2026-07-27	$4.77	$963,850,130	8 / 14
2026-07-28	$4.77	$963,850,130	8 / 14
2026-07-29	$2.38	$963,851,341	8 / 11
2026-07-30	$4.77	$963,850,130	8 / 14
2026-07-31	$2.38	$963,851,341	8 / 11
2026-08-01	$2.38	$963,851,341	8 / 11
2026-08-02	$2.35	$974,322,798	8 / 11
2026-08-03	$4.88	$974,321,560	8 / 14
2026-08-04	$2.35	$974,322,798	8 / 11
2026-08-05	$2.35	$974,322,798	8 / 11
2026-08-06	$5.00	$999,067,880	8 / 14
2026-08-08	$3.16	$1,073,198,623	7 / 11
2026-08-09	$3.16	$1,073,198,623	7 / 11
2026-08-10	$5.44	$1,061,862,510	8 / 14
2026-08-12	$3.16	$1,073,198,623	7 / 11
2026-08-13	$3.16	$1,073,198,623	7 / 11
2026-08-14	$3.16	$1,073,198,623	7 / 11
2026-08-15	$3.16	$1,073,198,623	7 / 11
2026-08-16	$3.16	$1,073,198,623	7 / 11
2026-08-17	$3.16	$1,073,198,623	7 / 11
2026-08-18	$3.16	$1,073,198,623	7 / 11
2026-08-19	$3.16	$1,073,198,623	7 / 11
2026-08-20	$3.16	$1,082,457,051	8 / 11
2026-08-21	$3.16	$1,082,457,051	8 / 11
2026-08-22	$3.16	$1,082,457,051	8 / 11
2026-08-23	$3.16	$1,082,457,051	8 / 11
2026-08-24	$3.16	$1,082,457,051	8 / 11
2026-08-25	$3.16	$1,082,457,051	8 / 11
2026-08-26	$3.16	$1,082,457,051	8 / 11
2026-08-27	$3.16	$1,082,457,051	8 / 11
2026-08-28	$3.16	$1,082,457,051	8 / 11
2026-08-29	$3.16	$1,082,457,051	8 / 11
2026-08-30	$3.16	$1,082,457,051	8 / 11
2026-08-31	$3.16	$1,082,457,051	8 / 11
2026-09-01	$3.16	$1,082,457,051	8 / 11
2026-09-02	$3.16	$1,082,457,051	8 / 11
2026-09-03	$3.16	$1,082,457,051	8 / 11
2026-09-04	$3.16	$1,082,457,051	8 / 11
2026-09-05	$3.16	$1,082,457,051	8 / 11
2026-09-06	$3.16	$1,082,457,051	8 / 11
2026-09-07	$3.16	$1,082,457,051	8 / 11
2026-09-08	$3.16	$1,082,457,051	8 / 11
2026-09-09	$3.16	$1,082,457,051	8 / 11
2026-09-10	$3.16	$1,082,457,030	8 / 11
2026-09-11	$3.16	$1,082,457,030	8 / 11
2026-09-12	$3.16	$1,082,457,030	8 / 11
2026-09-13	$3.16	$1,082,457,030	8 / 11
2026-09-14	$3.16	$1,082,457,030	8 / 11
2026-09-15	$3.16	$1,082,457,030	8 / 11
2026-09-16	$3.16	$1,082,457,030	8 / 11
2026-09-17	$3.16	$1,082,457,030	8 / 11
2026-09-18	$3.16	$1,082,457,030	8 / 11
2026-09-19	$3.16	$1,082,457,030	8 / 11
2026-09-20	$3.16	$1,082,457,030	8 / 11
2026-09-21	$3.16	$1,082,457,030	8 / 11
2026-09-22	$3.16	$1,082,457,030	8 / 11
2026-09-23	$3.16	$1,082,457,030	8 / 11
2026-09-24	$3.16	$1,082,457,030	8 / 11
2026-09-25	$3.16	$1,082,457,030	8 / 11
2026-09-26	$3.16	$1,082,457,030	8 / 11
2026-09-27	$3.16	$1,082,457,030	8 / 11
2026-09-28	$3.16	$1,082,457,030	8 / 11
2026-09-29	$3.16	$1,082,457,030	8 / 11
2026-09-30	$3.16	$1,082,457,030	8 / 11
2026-10-01	$3.16	$1,082,457,030	8 / 11
2026-10-02	$3.16	$1,082,457,030	8 / 11
2026-10-03	$3.16	$1,082,457,030	8 / 11
2026-10-04	$3.16	$1,082,457,030	8 / 11
2026-10-05	$3.16	$1,082,457,030	8 / 11
2026-10-06	$3.16	$1,082,457,030	8 / 11
2026-10-07	$3.16	$1,082,457,030	8 / 11
2026-10-08	$3.16	$1,082,457,030	8 / 11
2026-10-09	$3.16	$1,082,457,030	8 / 11
2026-10-10	$3.16	$1,082,457,030	8 / 11
2026-10-11	$3.16	$1,082,457,030	8 / 11
2026-10-12	$3.16	$1,082,457,030	8 / 11
2026-10-13	$3.16	$1,082,457,030	8 / 11
2026-10-14	$3.16	$1,082,457,030	8 / 11
2026-10-15	$3.16	$1,082,457,030	8 / 11
2026-10-16	$3.16	$1,082,457,030	8 / 11
2026-10-17	$3.16	$1,082,457,030	8 / 11
2026-10-18	$3.16	$1,082,457,030	8 / 11
2026-10-19	$3.16	$1,082,457,030	8 / 11
2026-10-20	$3.09	$1,082,457,051	8 / 11
2026-10-21	$3.09	$1,082,457,051	8 / 11
2026-10-22	$3.09	$1,086,016,408	8 / 11
2026-10-23	$3.09	$1,086,016,551	8 / 11
2026-10-24	$3.09	$1,086,016,551	8 / 11

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	14	1
2026-06-01	14	1
2026-07-01	14	1
2026-08-01	14	1
2026-09-01	14	1
2026-10-01	14	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 14 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

FILSPARI revenue growth and patient reachRevenue: $169.584M
Achieve 2026 revenue guidance rangeRevenue: $169.584M

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-33.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Travere Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a commercial growth and pipeline investment with elevated risk, not a proven profitable compounder: the company is currently loss-making, and management execution has been volatile. The long-term thesis is intact, with FILSPARI showing strong commercial momentum, while pipeline programs remain at earlier stages.

What's priced into Travere Therapeutics, Inc.

The valuation model describes expectations as justified, with no fragility signals, but shows a premium versus peers and low confidence. The negative expectations gap suggests the market may already be allowing for meaningful optionality, or future potential, rather than requiring a simple near-term earnings story.

What the fundamentals likely do

Near term, FILSPARI’s U.S. net product sales and new patient starts show strong growth, while the latest quarter was an earnings miss and another miss risk is elevated. Over the multi-year view, the HARMONY Phase 3 study is advancing toward topline data expected in the second half of 2027, and civorebrutinib broadens the pipeline but has no revenue yet. A CEO transition and potential guidance changes add uncertainty around execution.

What Travere Therapeutics, Inc. hinges on

The thesis depends on continued FILSPARI market expansion and progress in the clinical pipeline, especially HARMONY enrollment and its eventual data. Near-term risk rises if management cuts guidance or weak employment data increases recession concerns; stronger results and guidance from healthcare peers could support the sector backdrop.